Amylin, Takeda discontinue development of obesity treatment

Earlier on Thursday, Takeda Pharmaceutical Co. Ltd and Amylin Pharmaceuticals Inc. announced the discontinuation of the development of their combination obesity therapy, pramlintide/metreleptin.

The companies clarified that a commercial assessment has led to this decision. Christian Weyer, Senior vice president of research at Amylin said that they expect to develop a similar treatment with “less frequent dosing” in the future.
Since both companies have called off the development of their obesity treatment, neither one anticipates amending their latest fiscal 2011 guidance.

Leave a Reply